President Bush's request for fiscal year (FY) 2007 contained some unpleasant news for the cancer community, including a small but symbolically significant cut in funding for the National Cancer Institute (NCI).
President Bush's request for fiscal year (FY) 2007 contained some unpleasant news for the cancer community, including a small but symbolically significant cut in funding for the National Cancer Institute (NCI). "The NIH [National Institutes of Health] budget is flat, but the NCI budget is down 0.8%," John Niederhuber, md, the institute's COO, told the National Cancer Advisory Board (NCAB) after Mr. Bush sent his budget proposal to Capitol Hill.
The President asked Congress to provide the NIH $28.6 billion in FY 2007, the same amount that Congress appropriated for the current fiscal year but $66 million (0.2%) less than the agency received in FY 2005. For NCI, the new budget request sought $4.754 billion, down almost $40 million from the institute's FY 2006 appropriations of $4.793 billion and about $72 million below FY 2005. Because of inflation, the budget requests for NIH and NCI, if accepted and enacted by Congress, would mean a decrease in real dollars. NCI officials foresee a FY 2007 budget actually 3% to 4% below that of this year's appropriated funds.
The new budget plan envisions less money for NCI research project grants as well as other extramural research activities, cancer center support, training, and intramural research. The proposed NCI budget also includes $57.4 million (1.2% of the proposed budget) in funds that would be transferred to the NIH Director's Road Map Initiative, up from $42.8 million the institute must provide this year.
Thus, NCI's senior officials are under additional pressure to squeeze some institute programs to provide money for others, a difficult exercise that senior officials have endured since the ending of the 5 years of congressional largesse that nearly doubled NIH's annual budget.
Efficacy and Safety of Zolbetuximab in Gastric Cancer
Zolbetuximab’s targeted action, combined with manageable adverse effects, positions it as a promising therapy for advanced gastric cancer.
These data support less restrictive clinical trial eligibility criteria for those with metastatic NSCLC. This is especially true regarding both targeted therapy and immunotherapy treatment regimens.